BeiGene (6160.HK/BGNE.US) 22Q3 - The Price of Being an “Outlier”

Sales of current commercialized products isn't enough for BeiGene to turn loss into profit. BeiGene is fundamentally different from any other China pharmaceutical company.Investors need to aware of it

Equity Bottom-Up

330 Views, 28 Nov 2022 09:03

SUMMARY(Sign Up to Access)

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

Unlimited Research Summaries
Personalised Alerts
Custom Watchlists
Company Data & News
Events & Webinars

Trusted by:

Trusted by:

Already have an account? Sign In Now

Full Insight

(Paid Plans Only)

Discussions

(Paid Plans Only)

WHAT’S TRENDING

Insights

Trending
Latest

Top Quartile

Xinyao (Criss) Wang

HK/China Healthcare Analyst (ex-Fosun Pharma)

ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)

View Full Profile

Price Chart(Sign Up to Access)

Insight Stream

China Healthcare Weekly (Dec.2)- VBP Correction, Sales Ability Overweigh R&D, Expectation Difference
04 Dec 2022
Pre-IPO 3D Medicines (3DM HK) - Some Points Worth the Attention; Our Thoughts on Valuation
02 Dec 2022
Beijing Tiantan Biological Products (600161CH)-A Good Defensive Investment Target but May Overvalued
30 Nov 2022
BeiGene (6160.HK/BGNE.US) 22Q3 - The Price of Being an “Outlier”
28 Nov 2022
Akeso Biopharma (9926.HK) - The Recent Business Progress, the Valuation and the Challenges
07 Nov 2022
The Future Directions of A-Share After the 20th National Congress of the CPC
03 Nov 2022
Innovent Biologics Inc (1801.HK) - The Concerns and the Outlook
25 Oct 2022
BeiGene (6160.HK/BGNE.US) 22H1- It Is an Indisputable Fact that BeiGene Is Difficult to Make Profits
23 Aug 2022

Solutions
About
Legal
Contact
Download